Get the Stockscreener App
4.62
0.00%
0.00
After Hours:
4.68
0.06
+1.30%
Recursion Pharmaceuticals Inc stock is traded at $4.62, with a volume of 52.25M.
It is up +0.00% in the last 24 hours and down -11.66% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.62
Open:
$4.5
24h Volume:
52.25M
Relative Volume:
1.32
Market Cap:
$1.97B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-2.9806
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-16.30%
1M Performance:
-11.66%
6M Performance:
+10.26%
1Y Performance:
-33.33%
1-Day Range:
$4.18
$4.64
1-Week Range:
$4.18
$5.76
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.62 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Promising Biotech Stocks To ConsiderNovember 8th - MarketBeat
How to interpret RSI for Recursion Pharmaceuticals Inc. stockQuarterly Earnings Report & Fast Exit/Entry Strategy Plans - newser.com
Using Bollinger Bands to evaluate Recursion Pharmaceuticals Inc.July 2025 Macro Moves & AI Forecasted Stock Moves - newser.com
Top Biotech Stocks To Follow NowNovember 5th - MarketBeat
Recursion Pharmaceuticals Hits Day Low at $4.60 Amid Price Pressure - Markets Mojo
Will earnings trigger a reversal in Recursion Pharmaceuticals Inc.Risk Management & Verified Short-Term Trading Plans - newser.com
Recursion Pharmaceuticals Hits Day Low at $4.86 Amid Price Pressure - Markets Mojo
RXRX Revenue Miss Sparks Market Woes - timothysykes.com
Best Biotech Stocks To ConsiderNovember 6th - MarketBeat
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - simplywall.st
Will Recursion Pharmaceuticals’ (RXRX) New CEO Accelerate Its AI Ambitions and Strategic Partnerships? - Yahoo Finance
Recursion Pharmaceuticals Stock (RXRX) Opinions on Q3 Earnings Miss - Quiver Quantitative
Recursion Pharmaceuticals Faces Steep Revenue Miss Amid Market Pressures - StocksToTrade
RXRX Revenue Misses Q3 Expectations, Sparking Market Concerns - timothysykes.com
When is the best time to exit Recursion Pharmaceuticals Inc.Market Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Recursion refreshes leadership with CEO swap—Chutes & Ladders - Fierce Biotech
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Is it time to cut losses on Recursion Pharmaceuticals Inc.2025 Technical Overview & Growth Focused Stock Reports - newser.com
RXRX Faces Revenue Shortfall: Investor Panic? - timothysykes.com
Recursion outlines $800M cash runway through 2027 as leadership transition and partnership milestones drive next phase - MSN
Recursion Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Will RXRX Recover From Earnings Miss? - StocksToTrade
Recursion Pharmaceuticals (RXRX): Annual Losses Widen 35.2% Despite 30.1% Forecast Revenue Growth - Yahoo Finance
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y - Yahoo Finance
RXRX Stock Price and Chart — NASDAQ:RXRX - TradingView
How Recursion Pharmaceuticals Inc. stock reacts to bond yieldsJuly 2025 Gainers & Free Growth Oriented Trading Recommendations - newser.com
Recursion Pharmaceuticals: Q3 Earnings Snapshot - CT Insider
Recursion Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
RXRX Earnings Miss: What You Need to Know - timothysykes.com
How Recursion Pharmaceuticals Inc. stock valuations compare to rivalsCEO Change & Growth Oriented Trading Recommendations - newser.com
Decoding Recursion Pharmaceuticals Inc (RXRX): A Strategic SWOT Insight - GuruFocus
Recursion Pharmaceuticals: Q3 2025 Financial Highlights - TipRanks
Will Recursion Pharmaceuticals Inc. stock maintain growth storyAnalyst Upgrade & Free Real-Time Market Sentiment Alerts - newser.com
Recursion Pharmaceuticals (RXRX): Five-Year Loss Acceleration Challenges Bulls Despite 30.1% Revenue Growth Forecast - simplywall.st
Transcript : Recursion Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 05, 2025 - MarketScreener
Recursion picks J&J alum Khan to succeed Gibson as CEO - biocentury.com
Strong Financial Position and Strategic Leadership Drive Buy Rating for Recursion Pharmaceuticals - TipRanks
TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating - 富途牛牛
Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Recursion Pharmaceuticals, Inc. Announces CEO Changes, Effective January 1, 2026 - MarketScreener
Recursion Pharmaceuticals, Inc. Announces Management Changes, Effective January 1, 2026 - MarketScreener
Recursion Pharmaceuticals: Advancements and Leadership Transition Lead to Hold Rating - TipRanks
Recursion CEO Chris Gibson out as company head after 12 years - statnews.com
Recursion CEO Chris Gibson to step down as pressure builds to deliver in the clinic - Endpoints News
Recursion Q3 2025 slides: leadership change amid revenue miss - Investing.com
Earnings call transcript: Recursion Q3 2025 sees revenue miss, EPS beat - Investing.com
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - sharewise.com
Recursion’s Revenue Misses But Milestone Deals Keep Hopes Alive - Finimize
Recursion Pharmaceuticals Q3 Loss Widens, Revenue Falls - MarketScreener
Recursion announces CEO transition, Najat Khan to take helm in 2026 - Investing.com
Recursion Pharmaceuticals Announces New CEO Appointment - TipRanks
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):